Table 1.
Characteristics of People Prescribed Tenofovir Disoproxil Fumarate/Emtricitabine in the 12 Months Prior to Tenofovir Alafenamide/Emtricitabine Approval, Fenway Health, 1 October 2018–30 September 2019
| Characteristic | No. (%)a |
|---|---|
| Total | 2892 (100) |
| Age, y, mean (SD) | 38 (11.2) |
| Gender | |
| Cisgender man | 2774 (96.0) |
| Transgender woman | 42 (1.5) |
| Another gender | 40 (1.4) |
| Nonbinary | 34 (1.2) |
| Race | |
| White | 2108 (78.9) |
| Black or African American | 167 (6.3) |
| Multiracial | 163 (6.1) |
| Asian | 153 (5.7) |
| Another race | 52 (2.0) |
| Native Hawaiian or other Pacific Islander | 16 (0.6) |
| American Indian or Alaska Native | 14 (0.5) |
| Hispanic | 388 (14.8) |
| Insurance | |
| Private | 2439 (84.5) |
| Medicaid | 290 (10.1) |
| Medicare | 61 (2.1) |
| Uninsured | 49 (1.7) |
| Other public | 47 (1.6) |
| STI diagnosisb | 420 (14.5) |
| Reduced bone densityc | 16 (0.6) |
| Hypertensionc | 327 (11.3) |
| Diabetes mellitusc | 88 (3.0) |
| BMId, kg/m2, mean (SD) | 27 (5.0) |
| CrCle, mL/min, mean (SD) | 101 (22.3) |
| Total cholesterole, mg/dL, mean (SD) | 174 (36.1) |
| LDL-ce, mg/dL, mean (SD) | 104 (30.4) |
| HDL-ce, mg/dL, mean (SD) | 47 (13.2) |
Missing data were <0.1% for gender, 7.6% for race, 9.3% for ethnicity, 0.2% for insurance, 13.1% for BMI, 16.0% for CrCl, and 66.5% for lipids.
Abbreviations: BMI, body mass index; CrCl, creatinine clearance; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SD, standard deviation; STI, sexually transmitted infection.
aData are presented as No. (column %) unless otherwise indicated.
bSTI diagnosis included syphilis, gonorrhea, or chlamydia in the 12 months prior to October 2019.
cReduced bone density, hypertension, and diabetes mellitus were based on any diagnoses prior to October 2019.
dBMI was based on the most recent body weight and height prior to October 2019.
eCreatinine and lipids were the most recent in the 12 months prior to October 2019.